Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals
Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.
RAD
3.57%
2.7¢
RADIOPHARM THERANOSTICS LIMITED - News & Media
Market Cap $58.66M
!
Add to my watchlist
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.